33

Phospho-Met (Tyr1349) (130H2) Rabbit mAb



Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H M R	Sensitivity: Endogenous	MW (kDa): 145	Source/Isotype: Rabbit	UniProt ID: #P08581	Entrez-Gene Id: 4233		
Product Usage Information		Application Western Blotting		Dilution 1:1000				
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less t 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				ol and less than		
Specificity/Sensitivity		Phospho-Met (Tyr1349) (130H2) Rabbit mAb detects endogenous levels of Met only when phosphorylated at tyrosine 1349. This antibody may cross-react with other activated protein tyrosine kinases.						
Source / Purification		Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1349 of human Met.						
Background		Met, a high affinity tyrosine kinase receptor for hepatocyte growth factor (HGF, also known as scatter factor) is a disulfide-linked heterodimer made of 45 kDa α - and 145 kDa β -subunits (1,2). The α -subunit and the amino-terminal region of the β -subunit form the extracellular domain. The remainder of the β -chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl, and PI3 kinase (3). These fundamental events are important for all of the biological functions involving Met kinase activity. The addition of a phosphate at cytoplasmic Tyr1003 is essential for Met protein ubiquitination and degradation (4). Phosphorylation at Tyr1234/1235 in the Met kinase domain is critical for kinase activation. Phosphorylation at Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1 (5). Research studies have shown that altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon, and breast. Thus, investigators have concluded that Met is an attractive potential cancer therapeutic and diagnostic target (6,7).				1,2). The α-subunit emainder of the β- kinase activity. ich recruit several fundamental The addition of a gradation (4). ation. site for Gab1 (5).		
Background Re	kground References 1. Cooper, C.S. et al. (1984) Nature 311, 29-33. 2. Bottaro, D.P. et al. (1991) Science 251, 802-4. 3. Bardelli, A. et al. (1997) Oncogene 15, 3103-11. 4. Taher, T.E. et al. (2002) J Immunol 169, 3793-800. 5. Schaeper, U. et al. (2000) J Cell Biol 149, 1419-32. 6. Eder, J.P. et al. (2009) Clin Cancer Res 15, 2207-14. 7. Sattler, M. and Salgia, R. (2009) Update Cancer Ther 3, 109-118.							
Species Reactiv	vity	Species reactivity is de	etermined by testin	g in at least one approve	ed application (e.g.,	western blot).		
Western Blot B	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications K	ey	W: Western Blotting						
Cross-Reactivity Key H:		H: Human M: Mouse R: Rat						
Trademarks ar	nd Patents			of Cell Signaling Techno				
Limited Uses		more information. Except as otherwise ex the following terms ap	xpressly agreed in oply to Products pr	their respective owners. a writing signed by a leg- ovided by CST, its affiliate to, or different from, the	ally authorized repr es or its distributors	esentative of CST, . Any Customer's		

separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.